[
  {
    "question": "Typical hx of LBD, PET showed posterior CC abnormality (the pic is not obvious), what is Dx?",
    "option_a": "LBD (clear from the Hx).",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Dementia with Lewy bodies (DLB) is a neurodegenerative disorder characterized by fluctuating cognition, visual hallucinations, and Parkinsonian motor symptoms. Its identification relies on both clinical history and supportive neuroimaging findings. DLB is associated with the abnormal deposition of alpha-synuclein in cortical and brainstem neurons. On functional imaging such as FDG-PET scans, patients with DLB often show a characteristic pattern known as the 'cingulate island sign' where the posterior cingulate cortex is relatively spared compared to surrounding areas, differentiating it from Alzheimer\u2019s disease. Patients typically present with recurrent visual hallucinations, fluctuating attention and cognition, and features of parkinsonism. These symptoms combined with imaging features help differentiate DLB from other dementias. The diagnosis is made on clinical grounds supported by imaging. Differential diagnoses include Alzheimer\u2019s disease (typically with more prominent memory deficits and a different PET scan pattern showing posterior cingulate hypometabolism), vascular dementia, and frontotemporal dementia. FDG-PET findings such as the cingulate island sign add specificity toward DLB. Management includes cholinesterase inhibitors (e.g., rivastigmine) as first-line therapy to address cognitive fluctuations and hallucinations. Caution is necessary with antipsychotics due to severe sensitivity in DLB patients. Non-pharmacologic interventions and supportive care are also important. Although these patients are generally older and pregnancy/lactation is not an issue, in younger patients alternative agents with a safer profile may be considered. A. LBD (Dementia with Lewy bodies) \u2013 This is correct given the clinical history and the PET findings described. Other options that might have been listed could include Alzheimer\u2019s disease or other dementias; however, the presence of typical DLB features (especially the imaging finding, even if the image is not provided) supports DLB as the diagnosis. 1. The 'cingulate island sign' on FDG-PET is a supportive imaging marker for DLB. 2. DLB patients have marked sensitivity to antipsychotics, making their use risky. 3. Fluctuating cognition is a hallmark feature. Recent clinical guidelines emphasize the role of detailed clinical histories combined with functional imaging (PET/SPECT) in differentiating DLB from Alzheimer\u2019s disease. Studies highlight that maintaining cholinesterase inhibitors as a first line continuously yields cognitive and behavioral benefits.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with broca\u2019s aphasia. What is the localization:",
    "option_a": "frontoprietal operculum",
    "option_b": "",
    "option_c": "orrectly reflects the region that includes Broca\u2019s area (the inferior frontal gyrus, particularly its opercular part). Other potential options (if provided) might have included the posterior temporal lobe or other cortical regions, which would not match the classic clinical picture of Broca\u2019s aphasia.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Broca\u2019s aphasia is a language disorder characterized by non-fluent, effortful speech, with relatively preserved comprehension. It is traditionally linked to lesions in the dominant frontal lobe\u2019s language area. Damage to Broca\u2019s area, typically located in the posterior part of the inferior frontal gyrus (often referred to as the frontal operculum region), disrupts the neural networks responsible for speech production. This disruption results in agrammatism and impaired verbal output. Patients present with halting, telegraphic speech, and struggle to produce complex sentences while maintaining good comprehension. The deficit is observed when the lesion affects the left (dominant) hemisphere in most right-handed individuals. The diagnosis is primarily clinical. A detailed language and neurological evaluation, with confirmatory imaging (CT/MRI), will usually reveal a lesion to the left inferior frontal region. Differential diagnoses include other forms of aphasia (e.g., transcortical motor aphasia) where, for instance, comprehension might be more affected. The cornerstone of management is speech and language therapy, initiated as early as possible. In cases where stroke is the underlying cause, managing vascular risk factors is essential. Pharmacotherapy (e.g., dopaminergic agents) remains experimental and is often considered adjunctive. Pregnancy and lactation are usually not an issue in classical Broca\u2019s aphasia presentations as strokes predominantly occur in older populations. A. Frontoprietal operculum \u2013 This option correctly reflects the region that includes Broca\u2019s area (the inferior frontal gyrus, particularly its opercular part). Other potential options (if provided) might have included the posterior temporal lobe or other cortical regions, which would not match the classic clinical picture of Broca\u2019s aphasia. 1. Broca\u2019s aphasia is marked by effortful, nonfluent speech with relatively preserved comprehension. 2. The lesion is typically located in the dominant inferior frontal region. 3. Early rehabilitation can lead to significant improvements. Current research continues to support early, intensive speech therapy in post-stroke aphasia. Neuroimaging advances have reinforced the localization of Broca\u2019s area to the left inferior frontal cortex, underscoring its role in speech production.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Alzheimer pt presented with depression symptoms (sadness, insomnia) and agitation what you will give:",
    "option_a": "Cipralex",
    "option_b": "Trazadone",
    "option_c": "Quatipin",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer's disease (AD) is a neurodegenerative disorder that, in addition to cognitive decline, may present with neuropsychiatric symptoms such as depression, insomnia, and agitation. Addressing these symptoms is critical as they add to patient morbidity. Neurodegeneration in AD can disrupt neurotransmitter systems (notably cholinergic and serotonergic pathways), leading to mood disturbances and behavioral changes. SSRIs, such as Cipralex (escitalopram), work by increasing serotonin availability, which can help alleviate depressive symptoms and, in some studies, reduce agitation. Patients with AD may present with a spectrum of neuropsychiatric symptoms. Depression in AD is often characterized by sadness, anhedonia, sleep disturbances, and sometimes agitation. Treating depression in this context is important both for improving quality of life and potentially modulating other behavioral disturbances. Diagnosis of depression in AD is clinical, involving careful history-taking and assessment of mood symptoms relative to the patient\u2019s baseline cognitive function. Differential diagnoses include anxiety disorders, delirium, or behavioral disturbances solely due to the dementia process. First-line management for depression in AD involves SSRIs due to their efficacy and safety profile in the elderly. Cipralex (escitalopram) is often used since it has a relatively favorable side-effect profile. In cases where insomnia is prominent, adjunctive use of a low-dose sedating agent like trazodone may be considered. Antipsychotics such as quetiapine should be reserved for refractory cases with severe agitation or psychosis due to increased risks, including cerebrovascular events and mortality. For women who are pregnant or lactating (a rare scenario in AD, but applicable in early-onset cases), careful risk\u2013benefit analysis and consultation with psychiatry is warranted; SSRIs are generally considered relatively safe, but monitoring is essential. A. Cipralex \u2013 An SSRI that is first-line for depression in AD, with clinical studies supporting its utility in reducing depressive symptoms and even agitation. B. Trazadone \u2013 Although sedating and useful for sleep, it is not typically used as monotherapy for depression in this context. C. Quatipin (quetiapine) \u2013 An atypical antipsychotic that is generally reserved for severe behavioral disturbances and carries significant risks in dementia patients; not a first-line agent for depression. 1. SSRIs are considered first-line for managing depression in patients with Alzheimer\u2019s disease. 2. Antipsychotic use in dementia patients is associated with increased mortality and should be used with caution. 3. Non-pharmacologic interventions remain essential in managing neuropsychiatric symptoms in AD. Recent guidelines underscore the benefits of SSRIs in treating depression in the elderly with AD, noting that drugs like escitalopram can improve mood and reduce agitation. Large clinical trials and meta-analyses continue to support SSRIs over antipsychotics as initial therapy for these neuropsychiatric symptoms, with careful monitoring for side effects in vulnerable populations.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Description of pathology not picture (aquabin and alpha syncilin):",
    "option_a": "pick disease",
    "option_b": "Lewy body",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Lewy body pathology is defined by the presence of intracellular eosinophilic inclusions that primarily consist of misfolded alpha\u2010synuclein protein. This distinguishes it from other neurodegenerative disorders like Pick disease, which is associated with tau pathology and distinctly shaped Pick bodies. In disorders such as Dementia with Lewy Bodies and Parkinson\u2019s disease, misfolded alpha\u2010synuclein aggregates into insoluble fibrils, forming Lewy bodies. These inclusions disrupt neuronal function particularly in the substantia nigra and neocortical areas, leading to a range of neurological manifestations. The description provided in the question (mentioning alpha syncilin, considered a misnomer for alpha\u2010synuclein) is a hallmark of Lewy body pathology. Clinically, Lewy body pathology is associated with fluctuating cognition, visual hallucinations, and Parkinsonian motor features. Patients may present with episodes of confusion and motor disturbances while maintaining relative preservation of memory early in the disease course compared to Alzheimer\u2019s disease. Diagnosis is typically clinico-pathological with neuroimaging (e.g., DaTSCAN may support the diagnosis when Parkinsonism is present) and clinical criteria (e.g., the 2005 and 2017 criteria for Dementia with Lewy Bodies). Differential diagnoses include Alzheimer\u2019s disease, vascular dementia, and Pick disease, which can be differentiated by their distinct pathology \u2013 for instance, tau-positive inclusions in Pick disease. Management includes symptomatic treatment: cholinesterase inhibitors (e.g., rivastigmine) are often used as first-line therapy for cognitive symptoms, while careful use of dopaminergic agents may help motor symptoms. A tiered approach involves first addressing safety and symptomatic management, avoidance of neuroleptics due to severe sensitivity, and then non-pharmacologic interventions. Pregnancy and lactation are rarely factors with Lewy body disorders due to the age group affected, but treatment regimens would need careful adjustment if encountered in younger patients. Option B (Lewy body) is correct. Option A, Pick disease, is associated with different histopathological inclusions (Pick bodies containing tau proteins) and is not related to the alpha\u2010synuclein pathology described. 1. Alpha\u2010synuclein accumulation is the pathological hallmark of Lewy body disorders. 2. Lewy bodies are often seen in the brainstem and cortex in disorders such as Parkinson\u2019s disease and Dementia with Lewy Bodies. 3. Avoid antipsychotics in these patients due to a risk of severe adverse reactions. Recent studies support the use of cholinesterase inhibitors for managing cognitive symptoms in Dementia with Lewy Bodies, and ongoing research is exploring disease-modifying therapies targeting alpha-synuclein aggregation. Updated guidelines stress the importance of an accurate clinical diagnosis to avoid pitfalls associated with misdiagnosis.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "In MMSE what carry high weight",
    "option_a": "orientation",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "The Mini-Mental State Examination (MMSE) is a widely used cognitive screening tool that evaluates multiple cognitive domains including orientation, registration, attention, recall, language, and visuospatial skills. Cognitive decline in various conditions (such as Alzheimer\u2019s disease) often begins with dysfunction in multiple brain regions. The MMSE helps sample these functions through a fixed-point scoring system, with different domains affected differently depending on the underlying pathology. Orientation is a fundamental component of the MMSE that assesses a patient\u2019s awareness of time, place, and person. Impairment in orientation is often an early indicator of global cognitive dysfunction and is highly weighted in the test\u2019s overall score (10 out of 30 points). In cognitive assessments, evaluating orientation alongside memory, attention, and language enables clinicians to differentiate between normal aging, Mild Cognitive Impairment (MCI), and more advanced dementias. Differential diagnoses include delirium, depression, and other dementia subtypes. While the MMSE is itself a diagnostic tool, management after a cognitive deficit is identified involves further neuropsychological testing and addressing reversible causes if found. In special populations such as pregnant or lactating women, alternative assessments might be necessary if cognitive changes are suspected due to metabolic changes or mood disorders. Option A (orientation) is correct because orientation items contribute the highest weight (10 points) compared to other domains like registration (3 points) or attention (5 points), making them influential in the overall MMSE score. 1. Orientation constitutes roughly one-third of the total MMSE score and is highly sensitive to early cognitive impairment. 2. A decline in orientation scores often precedes other deficits in progressive dementias. 3. Always consider acute reversible causes of disorientation, such as delirium. Recent reviews reaffirm the importance of orientation in cognitive screening. Studies continue to validate the MMSE as a rapid assessment tool, though complementary tests (like the Montreal Cognitive Assessment) are also used, especially in early or mild cases.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "What suggest AD not LBD",
    "option_a": "Sleep disorder",
    "option_b": "Shuffling gait",
    "option_c": "Brain atrophy",
    "option_d": "Anterograde memory impairment",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s disease (AD) and Lewy Body Dementia (LBD) have overlapping features, but certain clinical aspects help in differentiating the two. One of the distinguishing features is the pattern of memory impairment. AD is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles (tau pathology), particularly in the hippocampus and medial temporal lobes, which are essential for forming new memories. In contrast, LBD is marked by abnormal alpha\u2010synuclein accumulation (Lewy bodies) and tends to affect cortical and subcortical regions differently. The pronounced anterograde memory impairment seen in AD reflects hippocampal pathology, making it a hallmark feature. LBD, on the other hand, tends to present with early visual hallucinations, fluctuating cognition, and Parkinsonian symptoms rather than the profound early memory deficits seen in AD. Differentiation between AD and LBD involves a detailed clinical history, cognitive testing, and neuroimaging. For instance, magnetic resonance imaging (MRI) in AD typically shows hippocampal atrophy, while dopamine transporter imaging and clinical features such as REM sleep behavior disorder lend support to LBD. Differential diagnoses also include vascular dementia and frontotemporal dementias. Management of AD involves cholinesterase inhibitors (donepezil, rivastigmine) and memantine as first-line agents for cognitive symptoms, with lifestyle modifications also playing an important role. In contrast, LBD management focuses on mitigating hallucinations and motor symptoms while avoiding medications that worsen parkinsonism. Although AD predominantly affects older adults, any pharmacologic intervention in pregnant or lactating patients would require careful risk\u2013benefit analysis and is rarely encountered. Option D (Anterograde memory impairment) is correct because it is a classical feature of AD due to hippocampal degeneration. Other options such as sleep disorder (common in LBD, often as REM sleep behavior disorder), shuffling gait (reflective of Parkinsonian features in LBD), and brain atrophy (a non-specific finding present in both conditions) are less discriminating. 1. Anterograde memory loss is a key early sign of AD. 2. Visual hallucinations and fluctuating cognition should prompt consideration of LBD. 3. Neuroimaging, particularly hippocampal volumetry, is useful in differentiating AD from LBD. Recent guidelines emphasize the role of biomarker and imaging techniques in differentiating AD from LBD. Research continues to refine clinical criteria and improve early diagnostic accuracy, with longitudinal studies underscoring the predictive value of early memory impairment for AD.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "MCI tx",
    "option_a": "Life style change",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) is considered a transitional stage between normal cognitive aging and outright dementia. It involves cognitive decline that is noticeable but not severe enough to interfere significantly with daily life. The underlying mechanisms of MCI are not fully elucidated but may represent early neurodegenerative changes or vascular insults. There is often a degree of neuronal loss and synaptic dysfunction in brain regions related to memory and executive function, albeit to a lesser extent than seen in full dementia. Patients with MCI typically present with mild memory lapses or difficulties with complex tasks, yet they maintain independence in daily activities. Consequently, early intervention can sometimes delay or prevent progression to dementia. Diagnosis of MCI involves a detailed clinical history, neuropsychological testing, and exclusion of other causes of cognitive decline such as depression, medication effects, or metabolic disturbances. Differential diagnoses include early Alzheimer\u2019s disease, depression (\u201cpseudodementia\u201d), and even normal aging. The current standard of care for MCI focuses primarily on non-pharmacologic interventions. First-line management includes lifestyle changes such as regular physical exercise, cognitive training, social engagement, and dietary modifications (e.g., a Mediterranean-style diet). Control of cardiovascular risk factors is also emphasized. There are no FDA-approved pharmacologic treatments for MCI at this time. These lifestyle measures are safe and easily applicable in pregnant and lactating women, where medication use is approached with caution. Option A (Life style change) is correct because lifestyle interventions are the cornerstone of MCI management. Other options, which are not provided in this question, would likely include pharmacological therapies that are not first-line or supported by current guidelines. 1. Lifestyle modifications, including exercise and cognitive training, are the most effective current interventions for MCI. 2. Regular monitoring is crucial as MCI may progress to dementia over time. 3. Risk factor management (e.g., hypertension, diabetes) is essential to reduce further cognitive decline. Recent studies have underscored the benefits of physical exercise, dietary interventions, and cognitive rehabilitation in slowing progression of MCI. Current guidelines continue to advocate for these non-pharmacologic approaches while research into potential disease-modifying agents remains ongoing.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "MCI what will change disease course",
    "option_a": "Vit E",
    "option_b": "Rivastigmine",
    "option_c": "Solanezumab",
    "option_d": ", implying that none of these agents change the disease course, is therefore the correct answer.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Dementia",
    "explanation": "Mild Cognitive Impairment (MCI) is a clinical syndrome in which there is a measurable cognitive decline greater than expected for a person\u2019s age and education level, but the deficits are not severe enough to interfere significantly with daily life. A core point is that while MCI may progress to Alzheimer\u2019s disease (AD) or other dementias, there is currently no treatment that reliably changes the natural disease course. MCI is thought to represent an intermediate stage between normal aging and dementia, often reflecting early neurodegenerative changes such as synaptic loss, beta\u2010amyloid deposition, and tau pathology. However, the underlying biological mechanisms vary, and despite many trials, no agent has been shown to modify the disease process reliably in this stage. Patients with MCI typically exhibit memory deficits or other cognitive impairments on neuropsychological tests but maintain independence in most activities of daily living. Though some treatments (such as cholinesterase inhibitors) have been studied, none have conclusively shown to alter the pathological progression from MCI to dementia. Diagnosis of MCI relies on careful clinical history, cognitive screening, and neuropsychological testing. Differential diagnosis includes early Alzheimer\u2019s disease, depression (pseudodementia), and other neurodegenerative or metabolic disorders. Imaging and laboratory tests are used to exclude reversible causes. Current management focuses on non-pharmacological interventions. First-line recommendations include lifestyle modifications (regular physical exercise, cognitive training, and a healthy diet such as the Mediterranean diet). Although various agents like vitamin E, cholinesterase inhibitors (e.g., rivastigmine), and anti-amyloid therapies (e.g., solanezumab) have been investigated, none have been shown to favorably alter the disease course. In pregnancy and lactation, non-pharmacologic measures are even more strongly favored due to the absence of safe, disease\u2010modifying drugs. Option A (Vitamin E) has been examined as an antioxidant but lacks robust evidence for disease modification in MCI. Option B (Rivastigmine) is a symptomatic treatment used in Alzheimer\u2019s disease but has not been shown to change the underlying progression of MCI. Option C (Solanezumab), an anti-amyloid monoclonal antibody, has failed to demonstrate a consistent impact on disease progression in clinical trials. Option D, implying that none of these agents change the disease course, is therefore the correct answer. \u2022 No current pharmacologic treatment has been proven to change the long\u2010term course of MCI. \u2022 Lifestyle modifications remain the cornerstone of MCI management. \u2022 Early identification through neuropsychological tests is key to enrollment in potential clinical trials. Recent consensus and guidelines from neurological societies emphasize that while research into disease\u2010modifying therapies continues, no medication (including vitamin E, cholinesterase inhibitors, or anti-amyloid drugs) has conclusively altered MCI progression. Current trials are increasingly focused on early intervention and lifestyle modification.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "AD clinical but pet scan normal next",
    "option_a": "Low 42 amyloid, high phost tau",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Alzheimer\u2019s disease (AD) is characterized by the accumulation of beta\u2010amyloid plaques and neurofibrillary tangles made of hyperphosphorylated tau. Biomarker evaluations (via PET imaging or cerebrospinal fluid analysis) are used to support a clinical diagnosis of AD. The accumulation of amyloid\u2010\u03b2 peptides in the brain occurs early in AD, while tau pathology (elevated phosphorylated tau and total tau) correlates more closely with neuronal injury. In some patients, especially in the early phases, imaging modalities like PET scans may not yet show abnormal amyloid deposition even though biochemical changes have begun. A patient with clinical features of AD who has a normal PET scan poses a diagnostic challenge. In such cases, the biochemical changes in the CSF\u2014specifically a decrease in amyloid\u2010\u03b242 and an increase in phosphorylated tau\u2014can provide evidence supporting AD pathology even when imaging is equivocal. The differential diagnosis includes other dementias such as frontotemporal dementia or vascular dementia. When clinical symptoms point toward AD but imaging is non-revealing, a lumbar puncture for CSF analysis is indicated to assess the levels of amyloid\u2010\u03b242 and tau proteins. While symptomatic management with cholinesterase inhibitors and memantine remains first-line, the emphasis here is on correctly establishing the diagnosis when PET imaging is inconclusive. In the context of pregnancy and lactation, standard diagnostic procedures (such as lumbar puncture) are generally safe, though radiologic studies should be considered carefully with regard to radiation exposure. Option A describes the typical CSF biomarker profile of AD (low amyloid\u2010\u03b242 and high phosphorylated tau) and is the appropriate next step when PET imaging is normal despite a supportive clinical picture. The other options are either blank or not provided, making Option A the clear and correct choice. \u2022 CSF biomarkers can be abnormal before PET imaging becomes positive in AD. \u2022 Low amyloid\u2010\u03b242 in the CSF, along with elevated tau, is highly supportive of AD pathology. \u2022 A normal PET scan does not entirely rule out AD in the early stages. Current guidelines endorse the use of CSF biomarkers in cases where there is a discordance between clinical evaluation and imaging findings. Newer research also highlights that CSF changes may precede amyloid PET abnormalities, underscoring their utility in early diagnosis.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Behavioral variant FTD normal semantic and language what is the pathology",
    "option_a": "TDP-43",
    "option_b": "FTD type A TDP",
    "option_c": "FTD type B TDP",
    "option_d": "FTD type C TDP",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD) is a heterogeneous group of disorders characterized by progressive changes in behavior, personality, and language. Behavioral variant FTD (bvFTD) primarily affects behavior with relative sparing of language, at least initially. FTD encompasses a range of underlying pathologies. One major category involves TDP-43 proteinopathies. Among these, different pathological subtypes (Type A, B, and C) have been identified. TDP-43 Type C is typically associated with the semantic variant of primary progressive aphasia, whereas TDP-43 Type A often shows prominent neuronal intranuclear inclusions and short dystrophic neurites and is more commonly seen in cases with language deficits as well as bvFTD with associated GRN mutations. In contrast, TDP-43 Type B pathology is most characteristically linked to the pure behavioral variant, particularly when language function is relatively preserved. Patients with bvFTD present with significant changes in personality and social conduct (disinhibition, apathy, and loss of empathy) but often maintain language ability in early stages. The absence of semantic and language deficits steers the pathology away from forms typically associated with semantic variant FTD. Diagnosing bvFTD involves a comprehensive assessment including behavioral evaluation, neuropsychological testing, and neuroimaging. Differential diagnoses include psychiatric disorders, Alzheimer\u2019s disease, and other neurodegenerative conditions. Neuropathologically, confirmation is only possible via post-mortem examination, but current clinical-pathological correlations help guide the presumptive pathology. Management of bvFTD is primarily supportive and symptomatic. First-line therapies focus on behavioral management, often including selective serotonin reuptake inhibitors (SSRIs) to help with disinhibition and compulsive behaviors. There are no disease-modifying treatments available. In patients who are pregnant or lactating, nonpharmacological and supportive measures are emphasized due to medication safety concerns. Option A (\u201cTDP-43\u201d) is too nonspecific. Option B (FTD Type A TDP) is more often associated with language impairment or cases with GRN mutations. Option C (FTD Type B TDP) is the classic pathological correlate for a behavioral variant with preserved language, making it the correct answer. Option D (FTD Type C TDP) is typically associated with the semantic variant of frontotemporal dementia, which is inconsistent with the scenario. \u2022 In bvFTD with preserved language functions, TDP-43 Type B pathology is the most common finding. \u2022 Differentiation of TDP-43 subtypes aids in correlating clinical presentation with underlying pathology. \u2022 There is significant heterogeneity in FTD, emphasizing the need for careful clinical and neuropsychological assessment. Recent neuropathological studies, including consensus classification systems, increasingly support that bvFTD with minimal language involvement is most frequently associated with TDP-43 Type B pathology. Ongoing research aims to better delineate these subtypes for potential targeted therapies in the future.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Clear scenario about HC asking about dx",
    "option_a": "HC",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Based on the phrasing and context provided, the scenario appears to describe a classic presentation of a neurological disorder commonly abbreviated as HC, which in many contexts refers to Huntington\u2019s Chorea (or Huntington\u2019s disease). Huntington\u2019s disease is a hereditary neurodegenerative disorder characterized by abnormal movements (chorea), cognitive decline, and psychiatric disturbances. Huntington\u2019s disease is caused by an autosomal dominant mutation in the HTT gene, resulting in an expanded CAG trinucleotide repeat. This expansion leads to a mutant huntingtin protein that aggregates within neurons, resulting in progressive neuronal dysfunction and death, predominantly in the striatum. Clinically, patients typically present in mid-life with choreiform movements, clumsiness, impaired coordination, and a variety of psychiatric symptoms (such as depression, irritability, and apathy), as well as gradual cognitive decline. A family history of similar symptoms is a key clinical clue. The diagnosis is based on clinical findings supported by genetic testing to confirm the expanded CAG repeats in the HTT gene. The differential diagnosis includes other causes of chorea (such as Wilson\u2019s disease, drug-induced chorea, or Sydenham\u2019s chorea), but the presence of a positive family history and the typical age of onset are distinguishing features. Management is largely symptomatic and supportive. First-line treatments for chorea include dopamine-depleting agents such as tetrabenazine or deutetrabenazine. Antipsychotics may also be used for behavioral disturbances. In pregnant or lactating patients, treatment choices must weigh maternal benefits against fetal or neonatal risks; many neuroleptics are used with caution, and genetic counseling is an important component of care. Option A (HC) is interpreted as the shorthand for Huntington\u2019s Chorea, which is the appropriate diagnosis given a clear clinical scenario consistent with its presentation. The other options are either not provided or irrelevant in this context. \u2022 Huntington\u2019s disease typically manifests with a triad of chorea, cognitive decline, and psychiatric symptoms. \u2022 A positive family history is a key element in the diagnosis. \u2022 Genetic testing confirming an expanded CAG repeat is diagnostic. Recent research in Huntington\u2019s disease is exploring gene silencing and other disease-modifying therapies, although current treatment remains symptomatic. Advances in neuroimaging and biomarkers are also improving early identification and monitoring of disease progression.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Imaging finding of CBD",
    "option_a": "(Temporal and parietal association involvement) is correct because FDG",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Dementia",
    "explanation": "Corticobasal Degeneration (CBD) is a neurodegenerative disorder that typically presents with asymmetric motor and cognitive deficits. Its imaging findings help support the clinical syndrome commonly known as Corticobasal Syndrome (CBS). CBD is classified as a tauopathy. Abnormal accumulation of hyperphosphorylated tau protein leads to neuronal degeneration, with a predilection for the cortical association areas\u2014especially the parietal and temporal lobes. This contributes to the asymmetric cortical atrophy and hypometabolism observed on imaging studies. Patients with CBD often demonstrate features such as apraxia, rigidity, and cognitive dysfunction including language disturbances. The imaging pattern showing asymmetric atrophy/hypometabolism in the parietal and temporal association cortices correlates with these deficits and contrasts with other neurodegenerative conditions that have different distributions of pathology. The diagnosis of CBD is established using a combination of clinical evaluation and neuroimaging (MRI, FDG-PET). Differential diagnoses include Progressive Supranuclear Palsy (PSP), Alzheimer\u2019s disease, and other atypical parkinsonian disorders. The pattern of asymmetric cortical involvement\u2014predominantly parietal and temporal\u2014is essential for differentiation. There is no current disease\u2010modifying therapy. Management is symptomatic and multidisciplinary, often involving physical therapy, occupational therapy, and speech therapy. Pharmacologic treatments include dopaminergic agents for parkinsonian features and possibly off\u2010label use of other medications to manage cognitive symptoms. In any case of neurodegenerative disease, pregnancy and lactation issues are less frequent as these disorders typically affect older adults; however, medication safety profiles must be reviewed if used in women of childbearing potential. Option a (Temporal and parietal association involvement) is correct because FDG-PET and MRI studies demonstrate asymmetric hypometabolism and atrophy in the temporal and parietal association cortices in CBD. Other options suggesting predominant involvement of the primary motor cortex, frontal lobe, occipital lobe, or isolated subcortical regions do not reflect the classical imaging pattern of CBD. 1. Asymmetry is a key imaging hallmark in CBD. 2. Involvement of the parietal and temporal association cortices correlates with features such as apraxia and cognitive deficits. 3. CBD is a tauopathy, making it distinct from other neurodegenerative disorders like Lewy Body Dementia. Recent research emphasizes the importance of advanced imaging modalities such as FDG-PET in early identification of CBD. Novel tau-directed therapies are under investigation, although none have yet demonstrated disease-modifying efficacy.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "LBD PET finding",
    "option_a": "(Occipital hypometabolism) is correct as it is considered a hallmark PET finding in LBD. Option b is a typographical error and not a recognized pattern; option c refers to Leigh syndrome (a mitochondrial encephalopathy of childhood), and option d pertains to disorders associated with brain iron accumulation, neither of which are relevant to LBD.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Lewy Body Dementia (LBD) is a progressive neurodegenerative disorder characterized by fluctuating cognition, visual hallucinations, and parkinsonism. Neuroimaging, particularly FDG-PET, has been used to support the diagnosis. LBD is associated with the accumulation of alpha-synuclein protein in cortical neurons. This pathological accumulation leads to neuronal dysfunction, with occipital involvement being a notable feature on PET imaging. Patients with LBD often experience prominent visual hallucinations and visuospatial deficits. These clinical symptoms correlate with occipital hypometabolism seen on FDG-PET scans, helping differentiate LBD from Alzheimer\u2019s disease where temporoparietal involvement is more typical. The differential diagnosis for LBD includes Alzheimer\u2019s disease, vascular dementia, and other parkinsonian syndromes. Occipital hypometabolism on PET is a distinguishing feature that, when combined with clinical history, aids in the diagnosis of LBD. Management involves a combination of cholinesterase inhibitors for cognitive symptoms, careful management of parkinsonism (with levodopa or dopamine agonists), and caution with antipsychotic use due to heightened sensitivity. In women of childbearing age, any pharmacologic therapy should consider potential teratogenic risks and effects during lactation, although LBD typically presents in older adults. Option a (Occipital hypometabolism) is correct as it is considered a hallmark PET finding in LBD. Option b is a typographical error and not a recognized pattern; option c refers to Leigh syndrome (a mitochondrial encephalopathy of childhood), and option d pertains to disorders associated with brain iron accumulation, neither of which are relevant to LBD. 1. Occipital hypometabolism on PET is strongly suggestive of LBD. 2. Visual hallucinations in LBD correlate with occipital lobe dysfunction. 3. Differentiating LBD from Alzheimer\u2019s disease is crucial because of differing treatment strategies, especially regarding the use of neuroleptics. Recent guidelines and studies stress the use of FDG-PET as a supportive tool in diagnosing LBD. Ongoing research focuses on improving the specificity of imaging biomarkers and exploring neuroprotective strategies.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Cbd case what is in Pet scan?",
    "option_a": "Asymmetrical hypometabolism in tempo-partial",
    "option_b": "Hypometabolism in precenttal and post central association cortex with asymmetry within the same hemisphere",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Corticobasal Degeneration (CBD) is characterized by its asymmetric clinical presentation and corresponding imaging findings. FDG-PET typically reveals a pattern of hypometabolism in certain cortical association areas that mirror the areas of clinical dysfunction. As a tauopathy, CBD involves the pathological deposition of tau protein leading to selective neuronal loss. This degeneration manifests as reduced metabolic activity primarily in cortical association areas, especially in the temporal and parietal lobes. Patients with CBD often exhibit apraxia, dystonia, and cognitive deficits. The associated hypometabolism in the temporal and parietal association cortices on PET imaging explains these higher-level cognitive and motor impairments. The differential diagnosis for a patient suspected of CBD includes Alzheimer\u2019s disease, frontotemporal dementia, and other atypical parkinsonian disorders. PET imaging plays a key role in differentiating these conditions by highlighting distinct regional hypometabolism patterns\u2014for CBD the temporal-parietal pattern is key. There is currently no cure for CBD; treatment is symptomatic and supportive. Therapies focus on physical rehabilitation, occupational therapy, and speech therapy. In the rare event of encountering younger patients (or women of childbearing potential), any medication use should be evaluated for safety in pregnancy and lactation, although CBD typically affects older adults. Option A, describing asymmetrical hypometabolism in the temporal and parietal (tempo-parietal) regions, is consistent with the classic imaging pattern seen in CBD. Option B, which suggests hypometabolism in the precentral and postcentral (sensorimotor) cortices with asymmetry, is less characteristic of CBD. The primary involvement in CBD is with association cortices rather than the primary sensorimotor areas. 1. Asymmetric metabolic deficits on PET are a hallmark of CBD. 2. The tempo\u2010parietal association areas are more typically involved than the sensorimotor cortices. 3. Recognizing the pattern on imaging helps differentiate CBD from other neurodegenerative syndromes. Recent studies have reinforced the role of FDG-PET in differentiating CBD from other conditions by emphasizing the distinct temporal-parietal hypometabolism. Advances in imaging techniques continue to improve early diagnostic accuracy and aid in the assessment of disease progression.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with agraphia, acalculia, and finger agnosia (Gerstmann Syndrome) what type of aphasia is associated with this",
    "option_a": "Anomia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Gerstmann Syndrome is a neuropsychological disorder typically resulting from a lesion of the dominant (usually left) inferior parietal lobule, particularly the angular gyrus. It is characterized by a cluster of deficits that include agraphia, acalculia, finger agnosia, and left-right disorientation. Damage to the angular gyrus disrupts the integration of sensory information required for tasks like writing, calculation, and finger recognition. This disruption can also affect language processing, leading to subtle naming difficulties known as anomic aphasia. Patients present with difficulties in writing and calculations as well as problems with fine motor skills (such as distinguishing fingers) and spatial orientation. When language is affected, it is often in the form of anomia, which is a mild aphasic disturbance marked by impaired word retrieval. The diagnosis is clinical and is supported by neuroimaging that shows lesions in the dominant parietal lobe (especially the angular gyrus). Differential diagnoses include other forms of aphasia such as conduction aphasia or transcortical sensory aphasia, but these conditions typically have additional language comprehension or repetition deficits. Management is primarily supportive and focused on rehabilitation. Occupational and speech therapy can help improve functional outcomes. In cases where an acute stroke causes these symptoms, standard stroke management protocols apply, with careful consideration for medication use in pregnancy and lactation if the patient is of childbearing age. Option A (Anomia) is correct because when the angular gyrus is involved, patients often develop word-finding difficulties, i.e., anomic aphasia. Other aphasia types (e.g., Broca\u2019s or Wernicke\u2019s aphasia) are not typically seen in Gerstmann Syndrome. 1. Gerstmann Syndrome is typically a result of lesions in the dominant angular gyrus. 2. The syndrome\u2019s components (agraphia, acalculia, finger agnosia, left-right disorientation) are key diagnostic clues. 3. Even when language is affected, the deficit is usually limited to naming (anomia) without broader comprehension or production impairments. Current neuroimaging studies reinforce the link between angular gyrus lesions and the manifestations of Gerstmann Syndrome. Recent reviews in aphasiology continue to support the association of anomic deficits with parietal lobe involvement, underscoring its relevance in differential diagnosis.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Resulting lesion due to lesion in the splenium of the corpus callosum",
    "option_a": "Alexia without agraphia",
    "option_b": "Agraphia without alexia",
    "option_c": "Alexia with agraphia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "The splenium of the corpus callosum is the posterior portion of this major white matter tract and plays a critical role in transferring visual information between the hemispheres. Specifically, its damage disrupts communication between the right visual cortex (which receives visual input from both visual fields) and the language centers in the left hemisphere. Damage to the splenium creates a disconnection syndrome whereby visual input processed in the right hemisphere cannot be relayed to the left hemisphere\u2019s language areas. Classically, this results in 'alexia without agraphia' where patients lose the ability to read while maintaining the ability to write. Although typically a left occipital infarct plus splenium involvement is described, isolated splenium lesions may also contribute to similar disconnection symptoms. Patients with alexia without agraphia are able to write and understand spoken language but cannot read written words. This dissociation is due to the interruption of the visual information flow to the left hemisphere\u2019s language centers, underscoring the role of interhemispheric communication in reading. Diagnosis typically involves neuroimaging (MRI) to demonstrate lesion localization. Differential diagnoses include left occipital lobe infarction without callosal involvement, other disconnection syndromes, or visual field defects. Neuropsychological testing confirms the dissociation between preserved writing and impaired reading. Management is primarily supportive and based on treating the underlying cause (e.g., thrombolysis for acute ischemic stroke, antiplatelet therapy, and risk factor management). Rehabilitation strategies include occupational and speech therapy for compensatory strategies. In pregnancy or lactation, any pharmacologic stroke management (e.g., antiplatelet drugs) should follow current guidelines which emphasize risk\u2013benefit assessments and the use of drugs with established safety profiles during these periods. Option A (Alexia without agraphia) is correct because it reflects the classic disconnection syndrome resulting from splenium lesions. Option B (Agraphia without alexia) is incorrect as isolated loss of writing ability is not typical for splenium involvement. Option C (Alexia with agraphia) incorrectly suggests loss of both reading and writing functions which is not the reported syndrome. 1. Patients with alexia without agraphia can still write even though they cannot read their own writing. 2. The integrity of the splenium is essential for the transfer of visual information to language-dominant regions in the left hemisphere. Recent neuroimaging studies have underscored the importance of white matter tract integrity in cognitive functions. Updated research in disconnection syndromes consistently supports the link between splenium lesions and alexia without agraphia, confirming that rehabilitative interventions should target compensatory strategies rather than expecting restoration of interhemispheric communication.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Gumaa-FTD pathology",
    "option_a": "TDP",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Frontotemporal dementia (FTD) encompasses a spectrum of neurodegenerative disorders predominantly affecting the frontal and temporal lobes. Its pathology is characterized by abnormal protein inclusions, with TDP-43 being one of the major proteins implicated. TDP-43 (transactive response DNA binding protein 43 kDa) is normally involved in DNA regulation. In certain FTD subtypes, abnormal accumulation and misfolding of TDP-43 within neurons leads to neurotoxicity, synaptic dysfunction, and ultimately, neuronal loss. These inclusions are a hallmark of many cases of FTD, particularly in those associated with motor neuron disease. Clinically, FTD is characterized by progressive changes in behavior or language. The type of protein inclusions (TDP-43 versus tau, for example) can correlate with specific clinical presentations and patterns of neurodegeneration, influencing both prognosis and management. Diagnosis is based on clinical evaluation, neuropsychological assessment, and neuroimaging (MRI, PET). Differential diagnoses include Alzheimer\u2019s disease, psychiatric disorders, and vascular dementia. Biomarkers and sometimes cerebrospinal fluid (CSF) analysis are being researched to better differentiate these pathologies. Currently, there is no disease-modifying therapy for FTD. Management is symptomatic and supportive, including behavioral interventions, speech therapy, and occupational therapy. Pharmacologic treatments (such as SSRIs for behavioral symptoms) are used cautiously. For pregnant or lactating women, non-pharmacologic therapy is generally preferred, and if medications are required, drugs with well-established safety profiles in these populations should be chosen. Option A (TDP) is correct as TDP-43 is one of the most frequently identified pathologic proteins in FTD. The absence of other options suggests focusing solely on this common pathology. Other proteins like tau and FUS are also found in FTD but are not as common as TDP-43 in the variants typically referenced in clinical questions. 1. FTLD-TDP is the most common pathological subtype of FTD. 2. Early behavioral and language changes are characteristic of FTD and can help differentiate it from other dementias. Recent pathological and genetic studies have reinforced the role of TDP-43 in FTD. International consensus criteria continue to support FTLD-TDP as a major subtype, and current research is exploring targeted therapies that might modify the disease process in the future.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Mild cognitive impairment still independent",
    "option_a": "Donepezil",
    "option_b": "Lifestyle modification",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Mild cognitive impairment (MCI) is considered an intermediate stage between normal cognitive aging and dementia. Patients with MCI exhibit measurable cognitive decline but maintain independence in daily activities. MCI can be due to various underlying pathologies including early Alzheimer\u2019s disease, vascular contributions, or other neurodegenerative processes. The subtle neuronal changes are often not severe enough to impede daily functioning, which differentiates MCI from dementia. Clinically, individuals with MCI have memory complaints or other cognitive deficits that are objectively measurable; however, their functional independence is preserved. This is a critical distinguishing feature from dementia, where daily functioning is impaired. Diagnosis relies on a combination of clinical evaluation, neuropsychological testing, and, when indicated, neuroimaging to rule out other causes of cognitive decline such as depression, medication side effects, or metabolic disturbances. Differential diagnoses include early dementia, depression, and normal age-related changes. The current best practice involves lifestyle modifications as the first-line management for MCI. This includes exercise, a healthy diet (e.g., Mediterranean diet), cognitive training, and social engagement. Pharmacologic interventions such as cholinesterase inhibitors (e.g., donepezil) are not routinely recommended for MCI due to limited evidence for efficacy and concerns regarding side effects. In pregnancy or lactation, lifestyle modifications are safe and preferred, avoiding unnecessary pharmacotherapy. Option A (Donepezil) is not supported as first-line therapy because studies have not convincingly demonstrated that cholinesterase inhibitors prevent progression from MCI to dementia. Option B (Lifestyle modification) is correct as current guidelines emphasize non-pharmacologic approaches as the mainstay of treatment for patients with MCI. 1. MCI patients retain their independence, distinguishing them from those with dementia. 2. Lifestyle modifications are the cornerstone of MCI management and may help delay progression to dementia. Recent research and meta-analyses stress the importance of modifiable risk factors in MCI management. There is insufficient evidence for the routine use of cholinesterase inhibitors in MCI, leading most guidelines to recommend lifestyle interventions as the safest and most beneficial initial approach.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Annual rate of conversion of MCI to Alzheimer's Dementia",
    "option_a": "is correct as it accurately reflects the epidemiologically supported conversion rate of 10",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Dementia",
    "explanation": "Mild cognitive impairment (MCI) is recognized as a risk state for progression to Alzheimer\u2019s dementia. Understanding the conversion rate is crucial for prognosis, counseling, and planning interventions. The pathophysiological changes underlying MCI, particularly when due to Alzheimer\u2019s disease, involve the accumulation of amyloid-beta plaques and tau neurofibrillary tangles. These changes cause synaptic dysfunction and neuronal loss, which eventually lead to clinical dementia. Patients with MCI exhibit cognitive decline while retaining independence in daily living. However, the progressive nature of the underlying pathology results in an estimated annual conversion rate of approximately 10-15% to Alzheimer\u2019s dementia, which has been supported by multiple cohort studies. Diagnosis involves clinical evaluation, cognitive testing, and often neuroimaging or biomarker studies (such as CSF or PET imaging) to identify early Alzheimer pathology. Differential diagnoses include stable MCI, reversible causes of cognitive decline (e.g., medication or metabolic disturbances), and other forms of dementia. Management of MCI focuses on risk factor modification including lifestyle interventions such as regular physical activity, diet optimization, cognitive training, and management of vascular risk factors. Pharmacologic treatment is not routinely recommended since cholinesterase inhibitors have not shown consistent benefits in delaying progression. In pregnancy and lactation, lifestyle modifications remain the safest and most applicable interventions. Option A is correct as it accurately reflects the epidemiologically supported conversion rate of 10-15% per year from MCI to Alzheimer\u2019s dementia. Other options proposing significantly lower or higher rates are not consistent with the bulk of the current data. 1. The annual conversion rate from MCI to Alzheimer\u2019s dementia is a critical prognostic indicator and is approximately 10-15% in specialized clinic populations. 2. Risk modification and lifestyle interventions are key in managing patients with MCI. Recent longitudinal studies and meta-analyses have consistently noted that 10-15% of MCI patients convert to Alzheimer\u2019s dementia annually. Newer biomarker advances are refining risk stratification, but the 10-15% figure remains a cornerstone in clinical prognostication and decision-making.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "LBD case, ask about pathology or inclusion",
    "option_a": "Tauopathy",
    "option_b": "Alpha synucleinopathy or Lewy Body",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Dementia",
    "explanation": "Lewy body dementia (LBD) is characterized by the presence of abnormal protein aggregates called Lewy bodies within neurons. These inclusions are composed primarily of misfolded alpha-synuclein, making LBD an alpha\u2010synucleinopathy. In LBD, alpha\u2010synuclein misfolds and aggregates inside neurons, particularly affecting brainstem nuclei, limbic regions, and cortical areas. This accumulation disrupts normal neuronal function and is distinct from tauopathies seen in Alzheimer\u2019s disease or certain other neurodegenerative disorders. Patients with LBD typically present with a triad of fluctuating cognition, visual hallucinations, and parkinsonian motor symptoms. The pathology underpins these clinical features; for example, alpha\u2010synuclein inclusions in the substantia nigra contribute to parkinsonism, while cortical involvement leads to cognitive fluctuations. Diagnosis is based on clinical criteria supplemented by neuroimaging (such as DaT scans which may demonstrate reduced dopaminergic uptake), polysomnography for REM sleep behavior disorder, and careful clinical history. Differential diagnoses include Alzheimer\u2019s disease (characterized by memory impairment and tau pathology) and Parkinson\u2019s disease dementia, which may have a more gradual onset of cognitive changes. First-line management includes cholinesterase inhibitors (e.g., rivastigmine) for cognitive symptoms, which have shown some benefit in LBD. Caution is advised with antipsychotics due to high sensitivity and risk of severe adverse reactions. In special populations such as pregnant or lactating women, treatment decisions require careful risk\u2013benefit analysis since data are limited; non-pharmacological measures are emphasized whenever possible. Option A (Tauopathy) is incorrect because tau pathology is a hallmark of Alzheimer\u2019s disease and other tauopathies, not LBD. Option B (Alpha synucleinopathy or Lewy Body) correctly identifies the underlying inclusion pathology in LBD. \u2022 Fluctuating cognition and prominent visual hallucinations in a dementia patient should raise suspicion for LBD.  \u2022 Antipsychotic sensitivity is a critical consideration in managing LBD patients. Recent guidelines stress the importance of early and accurate diagnosis using clinical criteria and biomarker support. Ongoing research into alpha\u2010synuclein-targeted therapies may, in the future, alter management strategies.",
    "exam_year": "2023",
    "exam_type": "Part II"
  }
]